Abstract
Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Biomarkers, Tumor / blood*
-
CA-125 Antigen / blood*
-
Calcitriol / administration & dosage
-
Calcitriol / adverse effects
-
Female
-
Humans
-
Isotretinoin / administration & dosage
-
Isotretinoin / adverse effects
-
Ovarian Neoplasms / blood*
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / immunology
Substances
-
Biomarkers, Tumor
-
CA-125 Antigen
-
Isotretinoin
-
Calcitriol